Interim Operational Guidelines on the Administration of Additional Doses of Pfizer-BioNTech COVID-19 Vaccine to Immunocompromised Pediatric A3 ages 12 to 17 Years Old

The memorandum provides interim operational guidelines on the administration of an additional dose of Pfizer-BioNTech COVID-19 vaccine to immunocompromised pediatric population (A3) ages 12 to 17 years old. It shall be given at least 28 days after the administration of the second dose of the primary series (English).